StonvexLoading…
StonvexStonvexStonvexCore line items from XBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $806.92K | $2.98M | $2.21M | $1.18M |
Operating Income | $-502.12K | $-2.83M | $-2.21M | $-1.67M |
Net Income | $-456.38K | $-2.68M | $-2.10M | $-1.59M |
EPS (Diluted) | $-0.20 | $-1.58 | $-1.36 | $-1.03 |
Total Assets | $7.91M | $8.36M | $5.07M | $5.35M |
Total Liabilities | $958.24K | $968.02K | $1.11M | $903.43K |
Cash & Equivalents | $7.35M | $7.88M | $4.12M | $4.78M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 2.29M | 2.29M | 1.54M | 1.54M |